• 18 years of age or older.

• Mean pulmonary artery pressure (mPAP) \> 25mmHg.

• Right heart dysfunction as evidence by at least one of the following:

∙ Tricuspid Annulus Plan Systolic Excursion (TAPSE) ≤ 16mm

‣ RV Fractional area change \< 35%

‣ RV systolic velocity \< 11.5 cm/s

‣ RV free wall strain \< 18%

‣ Lateral tricuspid annulus peak systolic velocity (S') \< 9cm/s

• Pulmonary compliance (C) \< 3.0 ml/mmHg

• Current assessment of WHO FC III or ambulatory IV

• Main pulmonary artery (MPA) diameter and anatomy suitable for placement of the device as defined in the Instructions For Use (IFU) and as assessed by multi-slice computed tomography (MSCT).

• Subject is deemed appropriate for Aria CV device by the Subject Care Team at the investigation site and approved by the Eligibility Review Committee (ERC).

• The subject has agreed to participate in the study by signing the study specific informed consent form.

• The subject agrees to abide by device related travel restrictions.

⁃ Pulmonary capillary wedge pressure (PCWP) ≤ 15mmHg

⁃ Pulmonary vascular resistance (PVR) \> 3 Woods Units (WU)

⁃ The subject remains symptomatic despite being on a stable drug regimen of PH specific medication(s) appropriate for their PH classification for at least 90 days prior to planned index procedure.

• 10\. Previous diagnosis of heart failure with preserved ejection fraction (HFpEF) (ejection fraction ≥ 50%) 11. PCWP \> 15 mmHg 12. PVR \> 3 WU

• 10\. Previous diagnosis of lung disease, including but not limited to chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) including idiopathic pulmonary fibrosis (IPF) or combined emphysema with fibrosis.

• 11\. PCWP ≤ 15mmHg 12. PVR \>4 WU